首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GLP2 |
| Uniprot No | P01275 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 53-89aa |
| 氨基酸序列 | HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA |
| 预测分子量 | 6.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GLP-2重组蛋白的3-4篇参考文献及其简要摘要：
---
1. **文献名称**：*Glucagon-like peptide-2: update on the translational biology and therapeutic potential*
**作者**：Drucker DJ
**摘要**：该综述系统总结了GLP-2的生物学功能，包括促进肠道黏膜生长、增强屏障功能及抑制细胞凋亡的分子机制，并探讨了重组GLP-2类似物(如替度鲁肽)在治疗短肠综合征和炎症性肠病中的临床应用潜力。
2. **文献名称**：*Teduglutide, a novel GLP-2 analog, in the management of short bowel syndrome: A systematic review and meta-analysis*
**作者**：Jeppesen PB et al.
**摘要**：通过临床试验分析，证实重组GLP-2类似物Teduglutide可显著改善短肠综合征患者的肠道吸收功能，减少肠外营养依赖，且安全性良好，支持其作为一线治疗药物的应用。
3. **文献名称**：*Design of a long-acting GLP-2 analog for enhanced therapeutic efficacy*
**作者**：Madsen K, Naimi RM
**摘要**：研究通过PEG化修饰重组GLP-2蛋白，显著延长其半衰期，并在动物模型中验证长效化GLP-2对肠黏膜修复的持续促进作用，为开发新型缓释制剂提供理论依据。
4. **文献名称**：*GLP-2 modulates gut inflammation and permeability in experimental colitis*
**作者**：Bremholm L et al.
**摘要**：实验表明重组GLP-2可通过抑制促炎因子表达和增强紧密连接蛋白生成，减轻结肠炎模型中的肠道炎症和渗漏，提示其在炎症性肠病治疗中的潜在价值。
---
这些文献涵盖基础机制、药物开发、结构优化及疾病应用，反映了GLP-2重组蛋白研究的核心方向。
Glucagon-like peptide-2 (GLP-2) is a 33-amino acid proglucagon-derived peptide hormone produced by intestinal enteroendocrine L-cells. It belongs to the incretin family and plays a critical role in regulating gastrointestinal homeostasis. GLP-2 exerts its biological effects by binding to the GLP-2 receptor (GLP-2R), a G protein-coupled receptor predominantly expressed in the gut, promoting intestinal epithelial proliferation, nutrient absorption, and mucosal integrity. Its trophic effects on the gastrointestinal tract make it a therapeutic candidate for disorders involving intestinal dysfunction.
Recombinant GLP-2 proteins are engineered using biotechnological methods to mimic the native peptide’s structure and function. Unlike natural GLP-2. which has a short half-life (<7 minutes) due to rapid degradation by dipeptidyl peptidase-4 (DPP-4), recombinant analogs like teduglutide feature amino acid substitutions (e.g., Ala2 to Gly2) to resist enzymatic cleavage, extending bioavailability to 2-3 hours. This modification enhances clinical utility, particularly for chronic conditions.
Therapeutic applications focus on short bowel syndrome (SBS), where GLP-2 analogs reduce dependence on parenteral nutrition by enhancing intestinal adaptation. Teduglutide, FDA-approved in 2012. demonstrates improved absorption and mucosal morphology in clinical trials. Research also explores potential roles in inflammatory bowel disease, chemotherapy-induced mucositis, and neonatal necrotizing enterocolitis.
Production involves recombinant DNA technology, typically using mammalian cell systems to ensure proper post-translational modifications. Challenges include optimizing pharmacokinetics and minimizing side effects like fluid retention. Ongoing studies investigate novel delivery systems and combination therapies to broaden clinical impact. As a gut-targeted regenerative agent, recombinant GLP-2 represents a paradigm shift in managing gastrointestinal insufficiency.
×
